Genzyme and Cystic Fibrosis Foundation Therapeutics collaborate
To support the discovery of new drugs to treat the most common mutation of CF
Genzyme, a Sanofi company, has entered a research agreement with Cystic Fibrosis Foundation Therapeutics to support the discovery of new drugs to treat the most common mutation found in patients with CF, Delta F508.
The focus of the agreement will be on identifying compounds known as ‘correctors’, which are believed to aid the ability of the malfunctioning CFTR protein found in CF patients to operate correctly.
In the Delta F508 mutation, the CFTR protein does not move to its proper place at the cell surface, impeding the flow of fluids into the airways.
Under the programme, researchers will evaluate different compound libraries for correctors for Delta F508, and will make use of the compound libraries of both Genzyme and Sanofi.
The research will take place at several Genzyme and Sanofi r&d facilities globally.
‘Genzyme’s capabilities and resources will help the CF Foundation accelerate its effort to find drugs to treat the most common mutation in CF and have the greatest impact on those with this disease,’ said Robert Beall, president and ceo of the CF Foundation.
